Upgrade to SI Premium - Free Trial

Outlook Therapeutics (OTLK) Misses Q3 EPS by 9c

August 14, 2026 7:37 AM

Outlook Therapeutics (NASDAQ: OTLK) reported Q3 EPS of ($0.09). Revenue for the quarter came in at $9 thousand.

For earnings history and earnings-related data on Outlook Therapeutics (OTLK) click here.

Categories

Earnings